During the United European Gastroenterology Week 2019 meeting, held in Barcelona, Spain, researchers presented results of a phase 1 pivotal study of a subcutaneously administered formulation of biosimilar infliximab, CT-P13 (Remsima, Inflectra), in patients with inflammatory bowel disease (IBD).
In September, Republic of Korea-based biosimilar developer Celltrion received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for its subcutaneous formulation of biosimilar infliximab, CT-P13 (Remsima, Inflectra), for the treatment of rheumatoid arthritis, and final authorization from the European Commission is expected in the coming weeks.
The biosimilar developer has also been investigating the novel formulation of the product in inflammatory bowel disease (IBD), and this week, during the United European Gastroenterology Week 2019 meeting, held in Barcelona, Spain, researchers presented results of a phase 1 pivotal study of the product in patients with IBD.
The findings, presented in a late-breaking abstract session, show that the subcutaneously administered biosimilar was noninferior to the intravenously administered version at week 22, and had comparable safety and efficacy up to week 30.
In the study, 136 patients with either Crohn disease (CD) or ulcerative colitis (UC) were given loading doses of intravenous CT-P13, at a dose of 5 mg per kg, at weeks 0 and 2. Then, they were randomized at week 6 to either receive a subcutaneous dose of 120 mg or 240 mg every 2 weeks, or to receive intravenous therapy at 5 mg per kg every 8 weeks. The primary endpoint was trough concentration at week 22. Noninferiority was prespecified as the lower bound of the 2-sided 90% confidence interval (CI) for the ratio of the geometric least squares mean being higher than 80%.
The lower bound of the 90% CI was greater than 80% at week 22, with higher geometric LS mean of trough concentration in the subcutaneous administration arm, and the researchers note that “Frequent administration of small doses and delayed absorption of [subcutaneous CT-P13] led to more constant exposure compared to [intravenous] dosing."
With respect to efficacy up to week 30, clinical response and remission were both induced and maintained and were comparable in both treatment arms. The combined clinical remission rates for patients with CD and UC at week 30 were comparable between the subcutaneous and intravenous arms, respectively (66.7% vs 54.7%; P = .1620).
Injection site reactions (ISRs) occurred more commonly in the subcutaneous arm, but all ISRs were grade 1 or 2 in intensity, and the safety profiles of the 2 CT-P13 products were generally similar. The incidence of antidrug antibodies was slightly lower in subcutaneous group at week 30 than in the intravenous group (37.9% vs 3.8%).
“CT-P13 [subcutaneous] infliximab has the potential to become the most innovative biosimilar treatment—improving convenience and allowing patients to have more control of their treatment in addition to direct clinical benefits,” said Stefan Schreiber, MD, PhD, director of the Clinic for Internal Medicine at Kiel Campus of the University Hospital Schleswig-Holstein in Germany, and first author of the study. “Not without reason the [intravenous/subcutaneous] sequence therapy that has been implemented into most development paths for novel molecules.”
In a statement, Celltrion noted that it plans to file for European regulatory approval for the subcutaneous formulation in IBD during the second half of 2020.
Reference
Schreiber S, Leszczyszyn J, Dudkowiak R, et al. Noninferiority of novel subcutaneous infliximab (CT-P13) to intravenous infliximab (CT-P13) in patients with active Crohn’s disease and ulcerative colitis: week 30 results form a multicenter, randomized controlled pivotal trial. Presented at: United European Gastroenterology Week 2019; October 29-23, 2019; Barcelona, Spain.
Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
May 18th 2024A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
May 11th 2024In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.